REGISTERED
on 09 Jan 2024
Last Applicant/ Owned by
E-28050 MADRID
ES
Serial Number
79340430 filed on 08th Apr 2022
Registration Number
7265231 registered on 09th Jan 2024
Correspondent Address
Vivian Ortiz-Ponce
Filing Basis
1. filing basis filed as 66 a
Disclaimer
NO DATA
IZAMBY
Biosimilar products for bone disease treatment, namely, biosimilar preparations for the treatment of osteoporosis, bone cancer, osteomyelitis, osteogenesis imperfecta, treatment of bone loss associated with hormonal suppression in men with prostate cancer at high risk of fractures, treatment of bone loss in men with prostate cancer undergoing hormonal suppression, and treatment to prevent risk of Read More
Classification Information
Class [005]
Pharmaceutical Products
Biosimilar products for bone disease treatment, namely, biosimilar preparations for the treatment of osteoporosis, bone cancer, osteomyelitis, osteogenesis imperfecta, treatment of bone loss associated with hormonal suppression in men with prostate cancer at high risk of fractures, treatment of bone loss in men with prostate cancer undergoing hormonal suppression, and treatment to prevent risk of vertebral fractures
First Use Date in General
N/A
First Use Date in Commerce
N/A
Mark Details
Serial Number
No 79340430
Mark Type
No Service/Collective Mark
Attorney Docket Number
No
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
Yes
66A Current
Yes
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 29th Apr 2024 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| 10th Apr 2024 | FINAL DISPOSITION NOTICE SENT TO IB |
| 10th Apr 2024 | FINAL DISPOSITION PROCESSED |
| 09th Apr 2024 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| 09th Jan 2024 | REGISTERED-PRINCIPAL REGISTER |
| 09th Jan 2024 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| 06th Nov 2023 | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB |
| 24th Oct 2023 | NOTIFICATION PROCESSED BY IB |
| 24th Oct 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 24th Oct 2023 | PUBLISHED FOR OPPOSITION |